| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MSH6; GTBP; DNA mismatch repair protein Msh6; hMSH6; G/T mismatch-binding protein; GTBP; GTMBP; MutS-alpha 160 kDa subunit; p160 |
| Entrez GeneID | 2956 |
| WB Predicted band size | Calculated MW: 153 kDa; Observed MW: 163 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human MSH6 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于MSH6抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome*
**作者**: Lindor NM, et al. (2006)
**摘要**: 该研究比较了免疫组化(IHC)检测错配修复蛋白(包括MSH6)与微卫星不稳定性(MSI)检测在筛查Lynch综合征中的效能，发现MSH6抗体缺失与MSI-H状态高度相关，支持IHC作为临床筛查工具。
---
2. **文献名称**: *Utility of immunohistochemistry in the evaluation of mismatch repair deficiency in Lynch syndrome-associated tumors*
**作者**: Shia J, et al. (2013)
**摘要**: 研究评估了MSH6抗体(克隆号44)与其他错配修复蛋白抗体在肿瘤组织中的敏感性和特异性，提出MSH6抗体染色异常可能提示罕见的Lynch综合征亚型或体细胞突变，需结合基因检测确认。
---
3. **文献名称**: *Clinicopathological differences of colorectal cancers with MSH6 defects compared with other mismatch repair-deficient cases*
**作者**: Batte BA, et al. (2014)
**摘要**: 分析MSH6缺陷结直肠癌的临床病理特征，发现其相较于其他MMR缺陷肿瘤(如MLH1/MSH2缺失)发病年龄更晚，且MSH6抗体表达缺失与特定的组织学亚型相关。
---
4. **文献名称**: *Expression of mismatch repair proteins in endometrial carcinoma*
**作者**: Buchynska LG, et al. (2020)
**摘要**: 研究MSH6抗体在子宫内膜癌中的表达模式，发现MSH6蛋白缺失与肿瘤分化程度及患者预后相关，提示其在子宫内膜癌分子分型中的潜在价值。
---
以上文献涵盖了MSH6抗体在肿瘤诊断、分型及遗传综合征筛查中的关键应用。如需具体引用，建议通过PubMed或学术数据库核对原文信息。
The MSH6 antibody is a critical tool in molecular pathology and cancer research, primarily used to assess the expression of the MSH6 protein, a key component of the DNA mismatch repair (MMR) system. Encoded by the *MSH6* gene, the MSH6 protein partners with MSH2 to form the MutSα complex, which identifies base-pair mismatches and small insertion-deletion loops during DNA replication. Defects in MSH6. often due to germline or somatic mutations, disrupt MMR function, leading to microsatellite instability (MSI) and increased cancer risk, notably in Lynch syndrome-associated cancers (e.g., colorectal, endometrial).
In diagnostic settings, MSH6 antibodies are employed in immunohistochemistry (IHC) to evaluate tumor tissue for loss of MSH6 protein expression, aiding in Lynch syndrome screening and MSI status determination. Loss of MSH6 staining, particularly when combined with intact MLH1/PMS2. suggests an MSH6-specific defect. In research, these antibodies help study MMR mechanisms, gene-editing outcomes, and therapeutic responses, such as predicting efficacy of immune checkpoint inhibitors in MSI-high tumors.
However, interpretation requires caution due to variables like antibody specificity, staining protocols, and tumor heterogeneity. False negatives/positives can arise, necessitating correlation with genetic testing or MSI-PCR. Overall, MSH6 antibodies remain indispensable for understanding MMR deficiencies and guiding precision oncology approaches.
×
